Welcome to our dedicated page for OLAPLEX HOLDINGS SEC filings (Ticker: OLPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olaplex Holdings, Inc. filings document the formal disclosures of a Nasdaq-listed beauty company with common stock registered under the symbol OLPX. Recent Form 8-K reports cover results of operations and financial condition, including sales performance across professional, specialty retail, and direct-to-consumer channels and U.S. and international markets.
The filing record also documents material definitive agreements, capital-structure disclosures, shareholder voting matters, governance changes, and compensatory arrangements. Company-specific disclosures include the completed acquisition of Purvala Bioscience by an Olaplex subsidiary, board composition updates, and other material-event reporting tied to the company’s hair-care innovation and public-company obligations.
Advent International-affiliated entities disposed of their entire reported stake in Olaplex Holdings through a tender offer. They tendered 499,468,771 shares of Common Stock at $2.06 per share in a disposition classified as pursuant to a tender offer, leaving 0 shares reported as beneficially owned after the transaction.
MORFITT MARTHA A M reported disposition transactions in this Form 4 filing.
Olaplex Holdings director Martha A. M. Morfitt fully exited her equity position as part of the company’s cash merger with Henkel US Operations Corporation. At the merger’s effective time, 411,833 shares of Common Stock held directly and by her spouse were converted into the right to receive $2.06 per share in cash.
In addition, 110,294 shares underlying her restricted stock unit awards were automatically cancelled and converted into a cash payment based on the same $2.06-per-share merger consideration. All 376,110 of her stock options, which had a $3.34 exercise price above the cash merger price, were cancelled for no consideration, leaving her with no remaining Olaplex equity or options.
OLAPLEX HOLDINGS, INC. insider filings show Advent International–affiliated entities reporting a full disposition of their indirect stake through a tender offer. The Form 4 lists a tender-offer disposition of 499,468,771 shares of common stock at $2.06 per share. Following this transaction, the reporting entities show 0 shares of Olaplex common stock held indirectly.
OLAPLEX HOLDINGS, INC. director and CEO Amanda Baldwin reported merger-related changes to her equity holdings. In connection with the merger in which Henkel US Operations Corporation acquired Olaplex, each share of common stock was converted into the right to receive $2.06 in cash at the effective time.
Baldwin disposed of 9,129,515 shares of common stock to the issuer at $2.06 per share and now reports no remaining common stock. Footnotes state that 7,910,624 shares underlying her restricted stock unit awards were automatically cancelled and converted into the right to receive the same cash merger consideration.
All 4,237,288 of her company stock options, which had a per-share exercise price of $2.53, were cancelled for no consideration because their exercise price exceeded the $2.06 merger price, leaving no remaining option holdings.
OLAPLEX HOLDINGS, INC. insider Kenneth F. Egan disposed of his common stock in connection with the company’s merger with Henkel US Operations Corporation. A total of 10,000 shares of common stock were transferred to the issuer at an effective price of $2.06 per share, leaving him with zero shares reported after the transaction.
Under the Agreement and Plan of Merger, each outstanding Olaplex common share was automatically converted at the effective time into the right to receive $2.06 in cash per share, and Olaplex became a wholly owned subsidiary of Henkel’s acquisition entity.
OLAPLEX HOLDINGS, INC. General Counsel John C. Duffy reported dispositions tied to the company’s merger with Henkel US Operations Corporation. At the merger’s effective time, his 971,384 common shares were converted into the right to receive $2.06 per share in cash.
The filing also notes 803,173 shares underlying his restricted stock units were cancelled and converted into the same cash consideration. In addition, 170,000 stock options with exercise prices of $5.41 and $14.95 per share were cancelled for no consideration, leaving him with no reported remaining shares or options.
OLAPLEX HOLDINGS, INC. officer Catherine Dunleavy reported a full disposition of her equity in connection with the company’s merger with Henkel US Operations Corporation. At the merger’s effective time, 3,026,885 shares of common stock were converted into the right to receive $2.06 per share in cash.
This total includes 2,705,329 shares underlying restricted stock unit awards that were automatically cancelled and converted into cash at the same $2.06 merger consideration. Following these transactions, Dunleavy held no Olaplex common shares.
OLAPLEX HOLDINGS, INC. director Tricia Glynn reported dispositions of Common Stock in connection with the closing of a cash merger. At the merger’s effective time, each share of Olaplex Common Stock was automatically converted into the right to receive $2.06 in cash per share.
The filing shows 499,468,771 indirectly held shares, managed by various Advent International funds, and 248,693 directly held shares were disposed of to the issuer at $2.06 per share, leaving zero reported holdings. The reported amount also reflects 110,294 shares underlying restricted stock unit awards that were cancelled and converted into cash at the same $2.06 merger consideration.
OLAPLEX HOLDINGS, INC. director Jerome Griffith reported a disposition of common stock tied to the company’s merger with Henkel US Operations Corporation. At the merger’s effective time, each Olaplex share was automatically converted into the right to receive $2.06 per share in cash.
The filing shows 110,294 shares underlying Griffith’s restricted stock unit awards were automatically cancelled and converted into the right to receive the same $2.06 per-share merger consideration. Following this cash-out transaction, the report shows Griffith with 0 shares of Olaplex common stock directly owned.